SLC4A1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: SLC4A1

NCBI ID: G6521

SLC4A1

SLC4A1: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

SLC4A1 (Sodium-Glucose cotransporter 4 alpha 1) is a gene that encodes a protein known as GLUT1. GLUT1 is a transmembrane protein that is involved in the transport of both sodium and glucose across the cell membrane. It is a key regulator of the endocytosis GLUT1 is also involved in the regulation of the production of new blood cells, as well as in the regulation of cell growth and differentiation.

SLC4A1 is a gene that has been identified as a potential drug target in the field of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and other aberrations in the brain. SLC4A1 is thought to be involved in the progression of these conditions, as it has been shown to be expressed in the brains of individuals with Alzheimer's disease and Parkinson's disease.

In addition to its potential role in neurodegenerative diseases, SLC4A1 is also a potential biomarker for these conditions. The production of SLC4A1 has been shown to be altered in the brains of individuals with Alzheimer's disease and Parkinson's disease, and it has been shown to be associated with the development of these conditions. Additionally, SLC4A1 has been shown to be a potential therapeutic target for these conditions, as inhibitors of SLC4A1 have been shown to protect against the progression of Alzheimer's disease and Parkinson's disease in animal models.

SLC4A1 is also involved in the regulation of the production of new blood cells, which is a critical process for maintaining the health and function of the body. It is known that SLC4A1 is involved in the regulation of the production of white blood cells, which are responsible for defending the body against infection. Additionally, SLC4A1 is also involved in the regulation of the production of red blood cells, which are responsible for transporting oxygen from the lungs to the rest of the body.

SLC4A1 is also involved in the regulation of cell growth and differentiation. It is known that SLC4A1 is involved in the regulation of cell proliferation, as well as in the regulation of cell differentiation. This is important for the development and maintenance of tissues and organs, as well as for the growth and development of the body.

In conclusion, SLC4A1 is a gene that has been identified as a potential drug target and biomarker for neurodegenerative diseases. Its involvement in the regulation of sodium and glucose transport, as well as its involvement in the regulation of blood cell production and growth and differentiation, make it a promising target for the development of new therapies for these conditions. Further research is needed to fully understand the role of SLC4A1 in these diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 4 Member 1 (Diego Blood Group)

Functions: Functions both as a transporter that mediates electroneutral anion exchange across the cell membrane and as a structural protein. Major integral membrane glycoprotein of the erythrocyte membrane; required for normal flexibility and stability of the erythrocyte membrane and for normal erythrocyte shape via the interactions of its cytoplasmic domain with cytoskeletal proteins, glycolytic enzymes, and hemoglobin. Functions as a transporter that mediates the 1:1 exchange of inorganic anions across the erythrocyte membrane. Mediates chloride-bicarbonate exchange in the kidney, and is required for normal acidification of the urine

The "SLC4A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC4A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets